Oncolytics Biotech/ CA6823101077 /
| 9/29/2023 9:59:52 PM | Chg. -0.03 | Volume | Bid10:25:00 PM | Ask12:00:05 AM | High | Low |
|---|---|---|---|---|---|---|
| 2.17USD | -1.36% | 5,850 Turnover: 11,230.14 |
-Bid Size: - | -Ask Size: - | 2.20 | 2.16 |
GlobeNewswire
12/12/2018
Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and t...
GlobeNewswire
12/3/2018
Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasom...
GlobeNewswire
11/29/2018
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer
GlobeNewswire
11/26/2018
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytru...
GlobeNewswire
11/12/2018
Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update
GlobeNewswire
11/9/2018
Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Me...
GlobeNewswire
11/5/2018
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporat...
GlobeNewswire
11/1/2018
Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep ...
GlobeNewswire
10/22/2018
Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS M...
GlobeNewswire
10/11/2018
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract f...
GlobeNewswire
10/2/2018
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Vir...
GlobeNewswire
9/28/2018
Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln...
GlobeNewswire
9/26/2018
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference
GlobeNewswire
9/17/2018
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and ...
GlobeNewswire
9/10/2018
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cance...
GlobeNewswire
9/6/2018
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibit...
GlobeNewswire
7/31/2018
Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference
GlobeNewswire
6/4/2018
Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote ...
GlobeNewswire
6/1/2018
Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares